Analyzing MoonLake Immunotherapeutics (MLTX) and Its Rivals

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) is one of 999 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare MoonLake Immunotherapeutics to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for MoonLake Immunotherapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0	0	11	0	3.00
MoonLake Immunotherapeutics Competitors	4427	15468	41829	752	2.62

MoonLake Immunotherapeutics currently has a consensus target price of $25.29, indicating a potential downside of 8.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 109.77%. Given MoonLake Immunotherapeutics’ peers higher possible upside, analysts clearly believe MoonLake Immunotherapeutics has less favorable growth aspects than its peers.

Volatility & Risk

MoonLake Immunotherapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics’ peers have a beta of 0.84, meaning that their average stock price is 16% less volatile than the S&P 500.

Insider and Institutional Ownership

76.1% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 40.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.2% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MoonLake Immunotherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-56.52%	-52.13%
MoonLake Immunotherapeutics Competitors	-3,956.09%	-828.57%	-36.90%

Valuation & Earnings

This table compares MoonLake Immunotherapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	-$49.97 million	-23.96
MoonLake Immunotherapeutics Competitors	$8.29 billion	$222.75 million	-4.22

MoonLake Immunotherapeutics’ peers have higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

MoonLake Immunotherapeutics peers beat MoonLake Immunotherapeutics on 7 of the 13 factors compared.

About MoonLake Immunotherapeutics

(Get Rating)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.